Journal Watch · Signal Transduction and Targeted Therapy · 2026
Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis.
By selectively blocking the prometastatic activity of TβRI-ICD without disrupting physiological TGFβ signaling, this strategy may provide a safer and more effective alternative to existing therapies for advanced prostate cancer.
TL;DR
By selectively blocking the prometastatic activity of TβRI-ICD without disrupting physiological TGFβ signaling, this strategy may provide a safer and more effective alternative to existing therapies for advanced prostate cancer.
Key findings
- Notably, the therapeutic effect was comparable to that of docetaxel, a current standard-of-care chemotherapy, without noticeable side effects on body weight, proximal aorta or heart function detected in immune-deficient mice.
- These findings suggest that targeting TβRI cleavage using specific mAbs is a novel precision medicine approach for the treatment of mCRPC.
- By selectively blocking the prometastatic activity of TβRI-ICD without disrupting physiological TGFβ signaling, this strategy may provide a safer and more effective alternative to existing therapies for advanced prostate cancer.
What they did
This cleavage, mediated by the metalloprotease ADAM17 (a disintegrin and metalloprotease domain 17; also known as TACE), results in the generation of a soluble intracellular domain (TβRI-ICD) that is translocated to the nucleus of castration-resistant prostate cancer (CRPC) cells and promotes epithelial-to-mesenchymal transition (EMT), invasion, and metastasis. High levels of TGFBR1 correlated with poor survival in two independent clinical cohorts of patients with mCRPC, and a strong positive correlation between TGFBR1 and ADAM17 expression was observed. In a preclinical human orthotopic mCRPC mouse model, treatment with therapeutic mAbs effectively prevented the nuclear accumulation of TβRI-ICD, inhibited EMT, and suppressed tumor growth, invasion, and metastasis.
Full abstract (original)
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains the primary cause of prostate cancer-related mortality. Despite the availability of treatments, the molecular mechanisms underlying tumor invasion and metastasis are not fully understood, highlighting the need for novel therapeutic strategies. In this study, we developed fully human monoclonal antibodies (mAbs) that prevent the proteolytic cleavage of the transforming growth factor-beta (TGFβ) type I receptor (TβRI) by steric hindrance.
What they did: This cleavage, mediated by the metalloprotease ADAM17 (a disintegrin and metalloprotease domain 17; also known as TACE), results in the generation of a soluble intracellular domain (TβRI-ICD) that is translocated to the nucleus of castration-resistant prostate cancer (CRPC) cells and promotes epithelial-to-mesenchymal transition (EMT), invasion, and metastasis. High levels of TGFBR1 correlated with poor survival in two independent clinical cohorts of patients with mCRPC, and a strong positive correlation between TGFBR1 and ADAM17 expression was observed. In a preclinical human orthotopic mCRPC mouse model, treatment with therapeutic mAbs effectively prevented the nuclear accumulation of TβRI-ICD, inhibited EMT, and suppressed tumor growth, invasion, and metastasis.
Results & conclusions: Notably, the therapeutic effect was comparable to that of docetaxel, a current standard-of-care chemotherapy, without noticeable side effects on body weight, proximal aorta or heart function detected in immune-deficient mice. These findings suggest that targeting TβRI cleavage using specific mAbs is a novel precision medicine approach for the treatment of mCRPC. By selectively blocking the prometastatic activity of TβRI-ICD without disrupting physiological TGFβ signaling, this strategy may provide a safer and more effective alternative to existing therapies for advanced prostate cancer.
Abstract © the authors / Signal Transduction and Targeted Therapy (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41392-026-02737-x · PubMed 42303991.
Why it matters for pharma & biotech
- Directly relevant to teams in antibody / ADC therapeutics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: antibody / ADC therapeutics
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Signal Transduction and Targeted Therapy study find?
By selectively blocking the prometastatic activity of TβRI-ICD without disrupting physiological TGFβ signaling, this strategy may provide a safer and more effective alternative to existing therapies for advanced prostate cancer.
What type of study is this?
It is a cohort / observational clinical study, published in Signal Transduction and Targeted Therapy in 2026. This cleavage, mediated by the metalloprotease ADAM17 (a disintegrin and metalloprotease domain 17; also known as TACE), results in the generation of a soluble intracellular domain (TβRI-ICD) that is translocated to the nucleus of castration-resistant prostate cancer (CRPC) cells and promotes epithelial-to-mesenchymal transition (EMT), invasion, and metastasis.
Where can I read the original paper?
The original is at the publisher via DOI 10.1038/s41392-026-02737-x. PubMed ID: 42303991. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/targeting-oncogenic-t-ri-signaling-inhibits-androgen-independent-prostat-02737x/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides